K Hedenmalm

Summary

Affiliation: Medical Products Agency
Country: Sweden

Publications

  1. ncbi Muscle toxicity with statins
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, Uppsala, Sweden
    Pharmacoepidemiol Drug Saf 19:223-31. 2010
  2. ncbi [Cardiovascular side-effects of triptanes in migraine exist but are rare. 5-HT receptor mediated extracranial vasoconstriction is the most common cause]
    K Hedenmalm
    Klinisk farmakologi, biverkningssektionen, Läkemedelsverket, Uppsala
    Lakartidningen 97:3078-84. 2000
  3. ncbi The conscientious judgement of a DSMB--statistical stopping rules re-examined
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, Box 26, 751 03, Uppsala, Sweden
    Eur J Clin Pharmacol 64:69-72. 2008
  4. ncbi Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs)
    Karin Hedenmalm
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Pharmacoepidemiol Drug Saf 15:719-25. 2006
  5. ncbi Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, Uppsala, Sweden
    J Clin Psychopharmacol 26:192-7. 2006
  6. ncbi Fatal venous thromboembolism associated with different combined oral contraceptives: a study of incidences and potential biases in spontaneous reporting
    Karin Hedenmalm
    Pharmacovigilance Unit and Clinical Trial Unit, Medical Products Agency, Uppsala, Sweden
    Drug Saf 28:907-16. 2005
  7. ncbi Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene
    Karin Hedenmalm
    Drug Epidemiology Unit, Medical Products Agency, 75103 Uppsala, Sweden
    Eur J Clin Pharmacol 60:369-72. 2004
  8. ncbi Prematurely ended phase III trials in Sweden during the years 2002-2008
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, P O Box 26, 751 03, Uppsala, Sweden
    Eur J Clin Pharmacol 67:869-75. 2011
  9. ncbi Pulmonary embolism associated with combined oral contraceptives: reporting incidences and potential risk factors for a fatal outcome
    Karin Hedenmalm
    Pharmacovigilance Unit, Medical Products Agency, Uppsala, Sweden
    Acta Obstet Gynecol Scand 83:576-85. 2004
  10. ncbi Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole)
    Karin Hedenmalm
    Drug Epidemiology Unit, Medical Products Agency, Box 26, 751 02 Uppsala, Sweden
    Eur J Clin Pharmacol 58:265-74. 2002

Detail Information

Publications17

  1. ncbi Muscle toxicity with statins
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, Uppsala, Sweden
    Pharmacoepidemiol Drug Saf 19:223-31. 2010
    ..Statins rarely cause serious muscle toxicity and rhabdomyolysis. The aim of our investigation was to identify and quantify potential risk factors for statin-induced rhabdomyolysis...
  2. ncbi [Cardiovascular side-effects of triptanes in migraine exist but are rare. 5-HT receptor mediated extracranial vasoconstriction is the most common cause]
    K Hedenmalm
    Klinisk farmakologi, biverkningssektionen, Läkemedelsverket, Uppsala
    Lakartidningen 97:3078-84. 2000
    ..Stroke, a known complication to migraine, has also been reported in patients treated with triptans, but available data do not suggest that triptans, when correctly used, greatly increase the risk...
  3. ncbi The conscientious judgement of a DSMB--statistical stopping rules re-examined
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, Box 26, 751 03, Uppsala, Sweden
    Eur J Clin Pharmacol 64:69-72. 2008
    ..A number of other studies in which complex decisions were made by DSMBs are also reviewed...
  4. ncbi Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs)
    Karin Hedenmalm
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Pharmacoepidemiol Drug Saf 15:719-25. 2006
    ..To study the association between alopecia and selective serotonin reuptake inhibitors (SSRIs) by estimating reporting rates and by making association comparisons within databases of adverse drug reactions (ADRs)...
  5. ncbi Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, Uppsala, Sweden
    J Clin Psychopharmacol 26:192-7. 2006
    ..This study aimed to investigate the potential risk factors for EPS associated with SSRIs including polymorphisms of cytochrome P-450 isoenzymes, and serotonin and dopamine transporters and receptors...
  6. ncbi Fatal venous thromboembolism associated with different combined oral contraceptives: a study of incidences and potential biases in spontaneous reporting
    Karin Hedenmalm
    Pharmacovigilance Unit and Clinical Trial Unit, Medical Products Agency, Uppsala, Sweden
    Drug Saf 28:907-16. 2005
    ..A further aim is to compare the characteristics of reported and not reported cases...
  7. ncbi Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene
    Karin Hedenmalm
    Drug Epidemiology Unit, Medical Products Agency, 75103 Uppsala, Sweden
    Eur J Clin Pharmacol 60:369-72. 2004
    ..This study aimed to investigate the importance of cytochrome P(450) enzymes for the reported interaction between tramadol and warfarin...
  8. ncbi Prematurely ended phase III trials in Sweden during the years 2002-2008
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, P O Box 26, 751 03, Uppsala, Sweden
    Eur J Clin Pharmacol 67:869-75. 2011
    ..An additional aim was to identify risk factors for a premature ending...
  9. ncbi Pulmonary embolism associated with combined oral contraceptives: reporting incidences and potential risk factors for a fatal outcome
    Karin Hedenmalm
    Pharmacovigilance Unit, Medical Products Agency, Uppsala, Sweden
    Acta Obstet Gynecol Scand 83:576-85. 2004
    ..This study aimed to identify such risk factors, and to calculate the reporting rates of fatal and non-fatal PE...
  10. ncbi Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole)
    Karin Hedenmalm
    Drug Epidemiology Unit, Medical Products Agency, Box 26, 751 02 Uppsala, Sweden
    Eur J Clin Pharmacol 58:265-74. 2002
    ..The aim of the study was to describe the pattern of blood dyscrasias associated with dipyrone, identify possible risk factors and calculate the incidence of agranulocytosis associated with dipyrone...
  11. ncbi Glucose intolerance with atypical antipsychotics
    Karin Hedenmalm
    Drug Epidemiology Unit, Medical Products Agency, Uppsala, Sweden
    Drug Saf 25:1107-16. 2002
    ..Early studies have also suggested an association between use of conventional antipsychotics and the development of glucose intolerance...
  12. ncbi [Reporting of side-effects--a system in need of improvement. Reporting of a physician questionnaire]
    Ylva Ekbom
    Biverkningsenheten, Läkemedelsverket, Uppsala
    Lakartidningen 99:3290-5. 2002
    ..The majority of the physicians who had a computer at work stated that they would like to access the reporting form electronically...
  13. ncbi Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series
    Anna K Jönsson
    Faculty of Health Sciences, Division of Clinical Pharmacology, Linkoping University, Linkoping, Sweden
    Int Clin Psychopharmacol 23:263-8. 2008
    ..Pulmonary embolism was overrepresented among medicolegal autopsy cases identified as users of low-potency first-generation and second-generation antipsychotics...
  14. ncbi [Relatively good safety in Swedish phase I trials. A survey of studies reported to the Medical Products Agency during 3 years]
    Anna Glazer
    , Uppsala
    Lakartidningen 105:2482-4. 2008
  15. ncbi Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives--an approach to specifying rates
    Eva Samuelsson
    Division of Family Medicine, Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden
    Eur J Epidemiol 20:509-16. 2005
    ....
  16. ncbi [Axillary vein thrombosis in a young woman with a contraceptive ring. Prothrombin gene mutation a possible connection]
    Eva Samuelsson
    , Ume
    Lakartidningen 104:32-4. 2007
  17. ncbi [A nation-wide survey: striking differences in the diagnostic procedures relating to thrombosis]
    Ola Björgell
    Röntgendiagnostiska avdelningen, Universitetssjukhuset MAS, Malmo
    Lakartidningen 99:4469-71. 2002
    ..The interpretation of nonfiling of contrast medium in vein segments on phlebography varied from DVT to no DVT. Most of the phlebographies were performed with digital X-ray technique...